Levnibiot

Levofloxacin, the active ingredient in Levnibiot, is a fluoroquinolone antibiotic presented as an intravenous solution for parenteral use. It treats a range of serious bacterial infections, including pneumonia, urinary tract, intra‑abdominal and skin infections, in adult patients, and is indicated for severe infections where oral therapy is insufficient, administered under medical supervision in inpatient settings.

GNH USA supplies Levnibiot as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide, providing reliable sourcing and regulatory support for high‑quality intravenous antibiotics.

Levnibiot (levofloxacin) is used to treat bacterial infections affecting several organ systems.

- Community‑acquired pneumonia: effective eradication of susceptible pathogens in adult patients. - Hospital‑acquired pneumonia: treatment of resistant bacterial strains in hospitalized individuals. - Complicated urinary tract infections: resolution of infection when oral agents are inadequate. - Complicated intra‑abdominal infections: control of polymicrobial infection following surgery or perforation. - Skin and soft tissue infections: clearance of bacterial involvement in severe cellulitis or abscesses.

Levnibiot may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset that usually resolves without treatment. - Diarrhea: loose stools, often self‑limiting but may lead to dehydration. - Headache: transient cranial discomfort, generally mild to moderate. - Dizziness: sensation of light‑headedness or vertigo, typically short‑lived. - Rash: mild skin erythema or itching without systemic signs.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain and loss of function, most often Achilles. - QT prolongation: lengthening of cardiac repolarization that can predispose to arrhythmias. - Severe allergic reaction: anaphylaxis with swelling, hives, and breathing difficulty. - Clostridioides difficile infection: severe colitis from disruption of normal gut flora. - Central nervous system effects: seizures, confusion, or psychosis, especially in vulnerable patients.

Before using Levnibiot, healthcare professionals should consider several precautionary measures.

- Renal function: assess creatinine clearance and adjust dose in impaired patients. - Hepatic impairment: evaluate liver function tests, as metabolism may be reduced. - Concomitant QT‑prolonging drugs: avoid or monitor due to additive cardiac risk. - History of tendon disorders: discontinue if tendon pain or inflammation occurs. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep below 25 °C, protect from light and moisture in original packaging.

Levnibiot can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids with aluminum or magnesium: reduce levofloxacin absorption; separate by ≥2 hours. - NSAIDs: increase risk of CNS stimulation and seizures. - Warfarin: may potentiate anticoagulant effect; monitor INR closely. - Theophylline: levofloxacin can raise its levels, risking toxicity.

Moderate Interactions (Monitor Closely): - Corticosteroids: combined use may increase tendon injury risk. - Diabetic agents (insulin, sulfonylureas): possible hypoglycemia; monitor glucose. - Oral contraceptives: slight reduction in efficacy; consider backup method. - Iron supplements: may bind drug and lower absorption; separate dosing.